2,6-Bis-methoxycarbonylamino-hexanoic acid | 111398-45-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,6-Bis-methoxycarbonylamino-hexanoic acid
• 英文别名: N2,N6-Bis(methoxycarbonyl)lysine；2,6-bis(methoxycarbonylamino)hexanoic acid
• CAS: 111398-45-9
• 化学式: C₁₀H₁₈N₂O₆
• 分子量: 262.263
• InChiKey: UUONLAKZGBJOET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,6-Bis-methoxycarbonylamino-hexanoic acid 在 4,4-二碘联苯 、 碘 作用下， 以 二氯甲烷 为溶剂， 生成 2-Methoxycarbonylamino-piperidine-1-carboxylic acid methyl ester
  参考文献：
  名称：

  由α-氨基酸和β-氨基醇一锅合成α-氨基膦酸酯

  摘要：

  α-氨基酸和β-氨基醇的一锅自由基裂解-磷酸化反应可提供高产率的α-氨基膦酸酯。该反应用于潜在的生物活性膦酸酯的合成。

  DOI：

  10.1016/j.tetlet.2005.09.019

文献信息

• [EN] NOVEL BENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
  申请人：ENANTA PHARM INC

  公开号：WO2013052369A1

  公开（公告）日：2013-04-11

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了式（I）的化合物，或其药学上可接受的盐、酯或前药：其抑制RNA含量的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者注射包含本发明化合物的制药组合物来治疗HCV感染的方法。
• MULTI-ARMED, MONOFUNCTIONAL, AND HYDROLYTICALLY STABLE DERIVATIVES OF POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS FOR MODIFICATION OF SURFACES AND MOLECULES
  申请人：Harris J. Milton

  公开号：US20100298496A1

  公开（公告）日：2010-11-25

  Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure wherein Z is a moiety that can be activated for attachment to biologically active molecules such as proteins and wherein P and Q represent linkage fragments that join polymer arms poly a and poly b , respectively, to central carbon atom, C, by hydrolytically stable linkages in the absence of aromatic rings in the linkage fragments. R typically is hydrogen or methyl, but can be a linkage fragment that includes another polymer arm. A specific example is an mPEG disubstituted lysine having the structure where mPEG a and mPEG b have the structure CH 3 O—(CH 2 CH 2 O) n CH 2 CH 2 — wherein n may be the same or different for poly a - and poly b - and can be from 1 to about 1,150 to provide molecular weights of from about 100 to 100,000.
• US20140341851A1
  申请人：——

  公开号：US20140341851A1

  公开（公告）日：2014-11-20
• CONJUGATE COMPRISING ERYTHROPOIETIN AND A BRANCHED POLYMER STRUCTURE
  申请人：CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA

  公开号：US20160317674A1

  公开（公告）日：2016-11-03

  The present invention discloses a conjugate comprising erythropoietin (EPO) and an asymmetric branched polymeric structure comprising two branches of monomethoxypolyethylene glycol (mPEG), where the molecular mass of one of these mPEG branches is between 10 kDa and 14 kDa, and the molecular mass of the other branch of mPEG is between 17 kDa and 23 kDa, as well as the pharmaceutical compositions containing it. The invention also provides a method for the preparation of pegylated EPO, wherein said protein is conjugated to an asymmetric branched polymeric structure with two branches of mPEG having the above described molecular masses.
• US7419600B2
  申请人：——

  公开号：US7419600B2

  公开（公告）日：2008-09-02